US2002168354A1PendingUtilityA1

psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia

59
Priority: Nov 10, 2000Filed: Nov 9, 2001Published: Nov 14, 2002
Est. expiryNov 10, 2020(expired)· nominal 20-yr term from priority
Inventors:Daria Mochly-Rosen
C12N 9/1205A61P 9/10A61K 38/08
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of reducing damage to cells and tissue caused by an ischemic or hypoxic event is disclosed. The method includes administering to the cell or tissue, either in vivo or ex vivo, ψεRACK peptide. The peptide can be administered before, during or after the ischemic or hypoxic event.

Claims

exact text as granted — not AI-modified
It is claimed:  
     
         1 . A method of reducing injury to a cell exposed to an ischemic or an hypoxic condition, comprising 
 administering to the cell a ψεRACK peptide.    
     
     
         2 . The method of  claim 1 , wherein said administering occurs prior to exposing the cell to said ischemic or hypoxic condition.  
     
     
         3 . The method of  claim 2 , wherein said administering prior to said ischemic or hypoxic condition is for a period of time of between about 1-180 minutes prior to said exposing.  
     
     
         4 . The method of  claim 1 , wherein said administering occurs after exposing the cell to said ischemic or hypoxic condition.  
     
     
         5 . The method of  claim 4 , wherein said administering after exposure to said ischemic or hypoxic condition occurs for between about 1-180 minutes after said ischemic or hypoxic condition.  
     
     
         6 . The method of  claim 1 , wherein said administering occurs during exposure of the cell to said ischemic or hypoxic condition.  
     
     
         7 . The method of  claim 1  wherein said administering includes administering a peptide having a sequence identified as SEQ ID NO:2.  
     
     
         8 . The method of  claim 1 , wherein said administering includes administering a peptide having a sequence selected from the group consisting of SEQ ID NOS:6-18.  
     
     
         9 . The method of  claim 1 , wherein said administering includes administering a ψεRACK peptide linked to a moiety effective to facilitate transport across a cell membrane.  
     
     
         10 . The method of  claim 9 , wherein the moiety is selected from the group consisting of a Tat-derived peptide (SEQ ID NO:5), an Antennapedia carrier peptide (SEQ ID NO:3), and a polyarginine peptide.  
     
     
         11 . The method of  claim 1 , wherein said administering includes administering the peptide by a route selected from the group consisting or intraveneous, parenteral, subcutaneous, inhalation, intranasal, sublingual, mucosal, and transdermal.  
     
     
         12 . A method of reducing injury to tissue exposed to an ischemic or an hypoxic condition, comprising 
 administering to the tissue a ψεRACK peptide.    
     
     
         13 . The method of  claim 12 , wherein said administering occurs prior to exposing the tissue to said ischemic or hypoxic condition.  
     
     
         14 . The method of  claim 13 , wherein said administering prior to said ischemic or hypoxic condition is for between about 1-180 minutes.  
     
     
         15 . The method of  claim 12 , wherein said administering occurs after exposing the tissue to said ischemic or hypoxic condition.  
     
     
         16 . The method of  claim 15 , wherein said administering after exposure to said ischemic or hypoxic condition occurs for between about 1-180 minutes after said ischemic or hypoxic condition.  
     
     
         17 . The method of  claim 12 , wherein said administering occurs during exposure of the tissue to said ischemic or hypoxic condition.  
     
     
         18 . The method of  claim 12 , wherein said administering includes administering a peptide having a sequence identified as SEQ ID NO:2.  
     
     
         19 . The method of  claim 12 , wherein said administering includes administering a peptide having a sequence selected from the group consisting of SEQ ID NOS:6-18.  
     
     
         20 . The method of  claim 12 , wherein said administering includes administering a ψεRACK peptide linked to a moiety effective to facilitate transport across a cell membrane.  
     
     
         21 . The method of  claim 12 , wherein the moiety is selected from the group consisting of a Tat-derived peptide (SEQ ID NO:5), an Antennapedia carrier peptide (SEQ ID NO:3), and a polyarginine peptide.  
     
     
         22 . The method of  claim 12 , wherein said administering includes administering the peptide by a route selected from the group consisting or intraveneous, parenteral, subcutaneous, inhalation, intranasal, sublingual, mucosal, and transdermal.  
     
     
         23 . The method of  claim 12  wherein said administering is to a tissue that is a whole organ ex vivo.  
     
     
         24 . The method of  claim 12  wherein said administering is to a tissue that is a whole organ in vivo.  
     
     
         25 . The method of  claim 23  or 24, wherein said organ is selected from the group consisting of heart, lung, liver, brain, and kidney.  
     
     
         26 . The method of  claim 24 , wherein said administering is by infusion through coronary arteries to an intact heart.

Join the waitlist — get patent alerts

Track US2002168354A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.